• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.

作者信息

Rubinstein Samuel M, Derman Benjamin A

机构信息

Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA.

Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.

出版信息

Eur J Cancer. 2023 Aug;189:112926. doi: 10.1016/j.ejca.2023.05.014. Epub 2023 Jun 10.

DOI:10.1016/j.ejca.2023.05.014
PMID:37307686
Abstract
摘要

相似文献

1
Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies.在多发性骨髓瘤的整个病程中感染率都很高，不仅仅是使用双特异性抗体时如此。
Eur J Cancer. 2023 Aug;189:112926. doi: 10.1016/j.ejca.2023.05.014. Epub 2023 Jun 10.
2
Addressing soluble target interference in the development of a functional assay for the detection of neutralizing antibodies against a BCMA-CD3 bispecific antibody.解决可溶性靶标干扰问题，开发针对 BCMA-CD3 双特异性抗体的中和抗体检测功能性分析方法。
J Immunol Methods. 2019 Nov;474:112642. doi: 10.1016/j.jim.2019.112642. Epub 2019 Aug 7.
3
Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma.用 B 细胞成熟抗原/CD3 双特异性抗体编码质粒 DNA 的基因治疗治疗多发性骨髓瘤。
Br J Haematol. 2023 May;201(3):417-421. doi: 10.1111/bjh.18230. Epub 2022 May 20.
4
Bi38-3 is a novel CD38/CD3 bispecific T-cell engager with low toxicity for the treatment of multiple myeloma.Bi38-3是一种新型的CD38/CD3双特异性T细胞衔接器，对治疗多发性骨髓瘤具有低毒性。
Haematologica. 2021 Apr 1;106(4):1193-1197. doi: 10.3324/haematol.2019.242453.
5
T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?双特异性抗体在多发性骨髓瘤中的应用：一场革命？
Blood. 2022 Jun 30;139(26):3681-3687. doi: 10.1182/blood.2021014611.
6
Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing.膜近端表位促进抗FcRH5/CD3高效形成T细胞突触，且是杀伤骨髓瘤细胞的必要条件。
Cancer Cell. 2017 Mar 13;31(3):383-395. doi: 10.1016/j.ccell.2017.02.001. Epub 2017 Mar 2.
7
[Bispecific antibodies in multiple myeloma].[多发性骨髓瘤中的双特异性抗体]
Bull Cancer. 2021 Oct;108(10S):S205-S212. doi: 10.1016/j.bulcan.2021.10.003.
8
BCMAxCD3 Bispecific Yields Robust Responses in Myeloma.BCMAxCD3 双特异性药物在骨髓瘤中产生强劲应答。
Cancer Discov. 2023 Jun 2;13(6):1280. doi: 10.1158/2159-8290.CD-NB2023-0034.
9
Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.用AMG 424靶向多发性骨髓瘤，AMG 424是一种新型抗CD38/CD3双特异性T细胞招募抗体，针对细胞毒性和细胞因子释放进行了优化。
Clin Cancer Res. 2019 Jul 1;25(13):3921-3933. doi: 10.1158/1078-0432.CCR-18-2752. Epub 2019 Mar 27.
10
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma.新型获批及即将面世的用于治疗复发/难治性多发性骨髓瘤的靶向 T 细胞的双特异性抗体。
J Oncol Pharm Pract. 2023 Apr;29(3):722-726. doi: 10.1177/10781552231154809. Epub 2023 Feb 12.

引用本文的文献

1
Supportive care in myeloma-when treating the clone alone is not enough.骨髓瘤的支持性护理——当仅治疗克隆细胞不足够时。
Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):569-581. doi: 10.1182/hematology.2024000579.
2
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.在1/2期MajesTEC-1研究中，COVID-19对复发/难治性多发性骨髓瘤患者使用替西帕单抗治疗结局的影响。
Blood Cancer J. 2024 Oct 21;14(1):186. doi: 10.1038/s41408-024-01160-1.
3
Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma.
关于统一多发性骨髓瘤双特异性抗体治疗期间感染报告的提案。
Blood Adv. 2024 Sep 24;8(18):4979-4982. doi: 10.1182/bloodadvances.2024013461.